Join our daily newsletter At The Bell to receive exclusive market insights
- Clinical-stage regenerative medicine company Regeneus (RGS) has been given a notice of intention for a European patent for its pain treatment Progenza
- Progenza is a cell therapy treatment that helps to reduces inflammation and promotes healing and repair in the damaged or diseased tissue
- The patent will give the treatment protection in Europe until 2032
- This follows the recent patents granted in the U.S. and Europe
- On market close for the day, Regeneus is up 14.3 per cent and is trading at 12 cents per share
Regeneus (RGS) has been given a notice of intention for a European patent for its pain treatment Progenza.
Progenza is a cell therapy treatment that helps to reduces inflammation and promotes healing and repair in the damaged or diseased tissue.
Once the patent is granted, it gives Regeneus protection for Progenza in Europe until 2032. This expands Progenza’s IP protection in Europe beyond the previously granted patent for the treatment of inflammatory conditions.
Last year, the company was granted a U.S. patent for the treatment and just last month was granted a patent in Japan.
“It is positive to see our patents being allowed and granted across the major European, U.S. and Japanese markets,” CEO Karolis Rosickas said.
“This patent will help facilitate our discussions with commercial partners for licensing Progenza for the $85.5 billion global pain market,” he added.
Notably, a phase one trial has already been completed on the treatment, which saw a significant reduction in knee pain and improvement in cartilage movement.
On market close for the day, Regeneus is up 14.3 per cent and is trading at 12 cents per share.
